ライフサイエンスコーパス: ixazomib

1 a response with 4 mg and 54% with 5.5 mg of ixazomib.

2 alone, and half dose CsA (5 mg/kg per day) + ixazomib.

3 and 5%, respectively) received single-agent ixazomib 0.24 to 2.23 mg/m(2) (days 1, 4, 8, 11; 21-day

4 l dose cyclosporine (CsA, 10 mg/kg per day), ixazomib (0.25 mg/kg on days -5, -2 and +2) alone, and h

5 hase 1, we gave patients escalating doses of ixazomib (1.68-3.95 mg/m(2)) to establish the recommende

6 d toxicity of combining 2 different doses of ixazomib (4 mg and 5.5 mg given weekly for 3 of 4 weeks)

7 Compared to untreated animals, ixazomib alone or in combination with (1/2) dose CsA red

8 cycles, followed by maintenance therapy with ixazomib alone.

9 of an investigational proteasome inhibitor, ixazomib, alone and in a CNI minimization strategy in a

10 olid tumors led to the invention of MLN9708 (ixazomib), an orally bioavailable next-generation protea

11 Weekly oral ixazomib appears to be active in patients with relapsed/

12 t that CNI minimization strategies including ixazomib are effective to prevent AMR including in sensi

13 heral neuropathy, and treated them with oral ixazomib (days 1, 8, 15) plus lenalidomide 25 mg (days 1

14 More importantly, ixazomib demonstrated potent anti-tumor efficacy in vivo

15 olled, 35 patients randomly assigned to each ixazomib dose.

16 m tolerated dose (MTD) of single-agent, oral ixazomib given weekly for 3 of 4 weeks.

17 e 4 severity occurred more frequently in the ixazomib group (12% and 7% of the patients, respectively

18 edian time to response was 1.1 months in the ixazomib group and 1.9 months in the placebo group, and

19 ence of peripheral neuropathy was 27% in the ixazomib group and 22% in the placebo group (grade 3 eve

20 similar in the two study groups (47% in the ixazomib group and 49% in the placebo group), as were th

21 he overall rates of response were 78% in the ixazomib group and 72% in the placebo group, and the cor

22 Rash occurred more frequently in the ixazomib group than in the placebo group (36% vs. 23% of

23 ree survival was significantly longer in the ixazomib group than in the placebo group at a median fol

24 ve ixazomib plus lenalidomide-dexamethasone (ixazomib group) or placebo plus lenalidomide-dexamethaso

25 atio for disease progression or death in the ixazomib group, 0.74; P=0.01); a benefit with respect to

26 ss the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethas

27 th creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dexamethas

28 ormed the subsequent clinical development of ixazomib in multiple myeloma.

29 study illustrates the anti-tumor efficacy of ixazomib in NB both alone and in combination with dox, s

30 ficacy of the oral proteasome inhibitor (PI) ixazomib in patients with relapsed/refractory immunoglob

31 of a second-generation proteasome inhibitor, ixazomib, in T-cell lymphoma and Hodgkin lymphoma cells

32 We demonstrated that ixazomib induced potent cell death in all cell lines at

33 dose CsA, the CNI minimization strategy with ixazomib inhibited AMR and allograft injury as evidenced

34 Ixazomib inhibits dox-induced NF-kappaB activity and sen

35 Ixazomib is an investigational, oral, proteasome inhibit

36 Ixazomib is an investigational, orally bioavailable 20S

37 Ixazomib is an oral proteasome inhibitor that is current

38 Ixazomib is the first investigational oral proteasome in

39 Ixazomib is the first oral proteasome inhibitor to enter

40 ment in progression-free survival (PFS) with ixazomib-lenalidomide-dexamethasone (IRd) compared with

41 t the second generation proteasome inhibitor ixazomib (MLN9708) not only inhibits NB cell proliferati

42 (Velcade(R)), carfilzomib (Kyprolis(R)), and ixazomib (Ninlaro(R)), confirms that proteasome inhibito

43 ents were noted in phase 1: one at a dose of ixazomib of 2.97 mg/m(2) and three at 3.95 mg/m(2).

44 possibilities (pomalidomide, carfilzomib and ixazomib, panobinostat, elotuzumab, and daratumumab).

45 The all-oral combination of weekly ixazomib plus lenalidomide and dexamethasone was general

46 d and refractory multiple myeloma to receive ixazomib plus lenalidomide-dexamethasone (ixazomib group

47 gression-free survival was observed with the ixazomib regimen, as compared with the placebo regimen,

48 in modification, and DNA repair processes in ixazomib-sensitive lymphoma cells.

49 Altogether, ixazomib significantly downregulates MYC and induces pot

50 genes from global transcriptome analysis for ixazomib strongly favored tumor inhibition via downregul

51 e, the second-generation PIs carfilzomib and ixazomib, the DACI panobinostat, and 2 mAbs, elotuzumab

52 The addition of ixazomib to a regimen of lenalidomide and dexamethasone

53 Furthermore, in ixazomib-treated lymphoma cells, we identified that CHK1

54 The terminal half-life of ixazomib was 3.3 to 7.4 days; plasma exposure increased

55 Ixazomib was administered to adult patients with relapse

56 The maximum tolerated dose of ixazomib was established as 2.97 mg/m(2) and the recomme

57 Overall, the ixazomib with dexamethasone has good efficacy in relapse

58 uggesting that combination therapy including ixazomib with traditional therapeutic agents such as dox